Stock Research Monitor: OSUR, OPGN, and ONVO
LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on RMD sign up now at www.wallstequities.com/registration. On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. US markets saw five out of nine sectors finishing the day in red and four in green. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares. The stock ended at $16.91, rising 1.32% from the last trading session. The stock is trading above its 50-day moving average by 0.23%. Furthermore, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 48.90.
On July 16th, 2018, research firm Stephens downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'. Get the full research report on OSUR for free by clicking below at:
San Diego, California headquartered ResMed Inc.'s stock finished yesterday's session 0.27% higher at $108.81. A total volume of 515,970 shares was traded. The Company's shares have gained 39.39% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 3.85% and 16.18%, respectively. Furthermore, shares of ResMed, which develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases, have an RSI of 61.42.
On July 02nd, 2018, research firm Goldman initiated a 'Buy' rating on the Company's stock. To experience our free membership services anytime/ anywhere and access the free report on RMD, click to register at:
At the close of trading on Thursday, shares in Gaithersburg, Maryland headquartered OpGen Inc. saw a drop of 3.83%, ending the day at $2.01. The stock recorded a trading volume of 49,837 shares. The stock is trading below its 50-day moving average by 1.97%. Moreover, shares of OpGen, which engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide, have an RSI of 51.08. Join our big investor community at Wall St. Equities today and get your free report on OPGN at:
San Diego, California headquartered Organovo Holdings Inc.'s shares ended the day 3.65% lower at $1.32 with a total trading volume of 742,793 shares. The stock has gained 17.86% in the previous three months. The Company's shares are trading below their 50-day moving average by 12.48%. Additionally, shares of Organovo Holdings, which provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases, have an RSI of 39.18. Know more about ONVO in our free research coverage at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities